

APPLICATION

FOR

UNITED STATES LETTER PATENT

BY

FRANK S. SKRALY

FOR

**POLYHYDROXYALKANOATE PRODUCTION BY COENZYME A-
DEPENDENT ALDEHYDE DEHYDROGENASE PATHWAYS**

POLYHYDROXYALKANOATE PRODUCTION BY COENZYME A-DEPENDENT ALDEHYDE DEHYDROGENASE PATHWAYS

Cross Reference to Related Applications

5 Priority is claimed to U.S. Provisional Application Serial No. 60/410,087 filed on September 16, 2002.

Background Of The Invention

The present invention is generally in the field of methods for making 2-hydroxyacid monomers, and the resulting polyhydroxyalkanoate polymers.

10 Numerous microorganisms have the ability to accumulate intracellular reserves of PHA polymers. Poly [(R)-3-hydroxyalkanoates] (PHAs) are biodegradable thermoplastic materials, produced from renewable resources, with a broad range of industrial and biomedical applications (Williams and Peoples, 1996, CHEMTECH 26, 38-44). Around 100 different monomers have been
15 incorporated into PHA polymers, as reported in the literature (Steinbüchel and Valentin, 1995, FEMS Microbiol. Lett. 128; 219-228) and the biology and genetics of their metabolism has recently been reviewed (Huisman and Madison, 1998, Microbiology and Molecular Biology Reviews, 63: 21-53).

To date, PHAs have seen limited commercial availability, with only the
20 copolymer poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) being available in development quantities. This copolymer has been produced by fermentation of the bacterium *Ralstonia eutropha*. Fermentation and recovery processes for other PHA types have also been developed using a range of bacteria including *Azotobacter*, *Alcaligenes latus*, *Comamonas testosterone* and
25 genetically engineered *E. coli* and *Klebsiella* and have recently been reviewed (Braunegg et al., 1998, Journal of Biotechnology 65: 127-161; Choi and Lee, 1999, Appl. Microbiol. Biotechnol. 51: 13-21). More traditional polymer synthesis approaches have also been examined, including direct condensation and ring-opening polymerization of the corresponding lactones (Jesudason and
30 Marchessault, 1994, Macromolecules 27: 2595-2602).

Synthesis of PHA polymers containing the monomer 4-hydroxybutyrate (PHB4HB, Doi, Y. 1995, Macromol. Symp. 98, 585-599) or 4-hydroxyvalerate and 4-hydroxyhexanoate containing PHA polyesters have been described (Valentin et al., 1992, Appl. Microbiol. Biotechnol. 36, 507-514 and Valentin et al., 1994, Appl. Microbiol. Biotechnol. 40, 710-716). These polyesters have been manufactured using methods similar to that originally described for PHBV in which the microorganisms are fed a relatively expensive non-carbohydrate feedstock in order to force the incorporation of the monomer into the PHA polyester. The PHB4HB copolymers can be produced with a range of monomer compositions which again provides a range of polymer (Saito, Y, Nakamura, S., Hiramitsu, M. and Doi, Y., 1996, Polym. Int. 39: 169).

PHA copolymers containing 3-hydroxyvalerate (3HV), especially poly-3-hydroxybutyrate-co-3-hydroxyvalerate (PHBV), has been available commercially under the trade name BiopolTM. PHBV has been produced commercially using *Ralstonia eutropha* (formerly *Alcaligenes eutrophus*) from carbohydrate feedstocks such as glucose in combination with a co-feed such as propionate, isobutyrate (Holmes et al., U.S. Patent 4,477,654) or odd chain length alcohols or fatty acids. A number of other microorganisms and processes are known to those skilled in the art (Braunegg et al. 1998, Journal of Biotechnology 65: 127-161). PHAs containing 3HV units have also been synthesized using recombinant microorganisms. *Escherichia coli* harboring the *R. eutropha* PHA biosynthesis genes has been used to produce PHBV from glucose and either propionate or valerate (Slater et al., 1992, Appl. Environ. Microbiol. 58:1089-1094). *Klebsiella oxytoca* harboring the *R. eutropha* PHA biosynthesis genes has been used to produce PHBV from glucose and propionate (Zhang et al., 1994, Appl. Environ. Microbiol. 60:1198-1205). *R. eutropha* harboring the PHA synthase gene of *Aeromonas caviae* was used to produce poly(3HV-co-3HB-co-3HHp) from alkanoic acids of odd carbon numbers (Fukui et al., 1997, Biotechnol. Lett. 19:1093-1097). U.S. Patent No. 6,329,183, to Skraly and Peoples, describes methods for producing PHA

copolymers comprising 3HV units from 1, 2-propanediol. PCT WO 00/43523 to Huisman *et al.*, describes method for producing PHAs comprising 3-hydroxyhexanoate (3HH) monomer units from butyrate or butanol co-feeds. In each of these cases, the alcohol co-feed was converted into the free acid which
5 was then activated to the Co-enzyme A thioester by the action of a fatty acyl-coenzymeA synthetase or fatty acyl-CoA transferase. In some cases the enzyme activity was endogenous to the host strain and in others this activity was provided by genetic engineering.

Genes and techniques for developing recombinant PHA producers
10 suitable for practicing the disclosed invention are generally known to those skilled in the art (Madison and Huisman, 1999, Microbiology and Molecular Biology Reviews, 63: 21-53; PCT WO 99/14313).

3HV copolymers have proven useful in a range of applications. In some cases PHBV copolymers with a 3HV level of around 7-12% by weight co-
15 monomer are adequate. In other cases a 3HV level of 15-30 % by weight is more useful (EP LATEX). Higher levels of 3HV are accomplished by increasing the level of propionic acid in the feed. However, there are two negative consequences associated with this strategy. First, propionic acid is toxic to the cells and, therefore, reduces the rate of growth and polymer production
20 representing a significant increase in the cost of production. The second effect is that some of the propionic acid can be used for other metabolic processes and is therefore not incorporated into the polymer. As the propionic acid is the most expensive of the feed components, this represents another increase in the cost of production. Therefore, it would be desirable to develop microbial systems that
25 produce 3HV copolymers with higher productivities and better yields on the co-feed.

It is therefore an object of the present invention to provide methods and microbial strains suitable for producing PHA polymers or copolymers that avoids increasing the level of 3-hydroxyacid in the feed.

It is a further object of the present invention to provide methods and microbial strains suitable for production of PHA polymers containing 3HV units that avoids the use of 3-propionic acid in the feed.

Summary Of The Invention

- 5 Organisms are provided containing genes encoding one or more of Coenzyme-A-dependent aldehyde dehydrogenase, acyl-CoA transferase, acyl-CoA synthetase, β -ketothiolase, acetoacetyl-CoA reductase and PHA synthase. In some cases one or more of these genes are native to the host organism and the remainder are provided from heterologous genes through genetic engineering.
- 10 These organisms produce poly (3-hydroxyalkanoate) homopolymers or co-polymers comprising 3-hydroxyalkanoate monomers other than 3-hydroxybutyrate wherein these 3-hydroxyalkanoate units are derived from the enzyme-catalyzed conversion of alcohols to 3-hydroxyacyl-CoA monomers and wherein at least one step in the conversion pathway involves a Co-enzyme A-
- 15 dependent aldehyde dehydrogenase activity.

 The PHA polymers are readily recovered and industrially useful as polymers for articles such as films, latexes, coatings, adhesives, fibers, binders, resins and various medical devices. The medical device can be used for, for example, controlled release of therapeutic, prophylactic or diagnostic agents,

20 tissue engineering scaffolds, cell encapsulation, targeted delivery, biocompatible coatings, biocompatible implants, guided tissue regeneration, wound dressings, orthopedic devices, prosthetics, bone cements, or diagnostics.

Brief Description Of The Drawings

 Figure 1 shows the pathways leading to the formation of propionyl-CoA

25 from propylene glycol and 1-propanol and butyryl-CoA from butanol.

 Figure 2 shows the growth rates of *E. coli* strain MBX1335 in the presence of no inhibitor, propionate, or 1-propanol.

Detailed Description Of The Invention

I. Polyhydroxyalkanoate (PHA) Compositions

As used herein, "PHA materials" contain one or more units, for example between 10 and 100,000, and preferably between 100 and 30,000 units of the

5 following formula I:



and one or more units, for example between 1 and 100,000, and preferably between 10 and 30,000 units of the following formula II:



10 wherein n is an integer, for example between 1 and 15, and in a preferred embodiment, between 1 and 4;

wherein m is an integer, for example between 0 and 15, and in a preferred embodiment, between 0 and 4; and

wherein R^1 , R^2 , R^3 , and R^4 independently can be hydrogen or
15 hydrocarbon radicals including long chain hydrocarbon radicals; halo- and hydroxy-substituted radicals; hydroxy radicals; halogen radicals; nitrogen-substituted radicals; and/or oxygen-substituted radicals.

As used herein, the formula $-(\text{CR}^3\text{R}^4)_n-$ or $-(\text{CR}^3\text{R}^4)_m-$ is defined as including the following formulas:

20 $-\text{CR}^3\text{R}^4-$ (where n or m=1);

$-\text{CR}^3\text{R}^4\text{CR}^{3'}\text{R}^{4'}-$ (where n or m=2); and

$-\text{CR}^3\text{R}^4\text{CR}^{3'}\text{R}^{4'}\text{CR}^{3''}\text{R}^{4''}-$ (where n or m=3);

wherein R^3 , R^4 , $\text{R}^{3'}$, $\text{R}^{4'}$, $\text{R}^{3''}$, and $\text{R}^{4''}$ can be independently hydrocarbon radicals including long chain hydrocarbon radicals; halo- and
25 hydroxy-substituted radicals; hydroxy radicals; halogen radicals; nitrogen-substituted radicals; oxygen-substituted radicals; and/or hydrogen atoms. Thus, formula I or formula II includes units derived from 3-hydroxyacids (n or m=1), 4-hydroxyacids (n or m=2), and 5-hydroxyacids (n or m=3). Formula II includes units derived from 2-hydroxyacids (m=0), for example lactic acid. or
30 glycolic acid.

The polymers typically have a molecular weight over 300, for example between 300 and 10^8 , and in a preferred embodiment 10,000 to 10,000,000 Daltons.

In a representative embodiment, the PHA polymer is a copolymer containing 3HV units. In another embodiment, the PHA polymer is a copolymer containing 3HH units.

II. Method for biosynthesis of PHAs containing 2-hydroxyacid monomer

(1) Synthesis of polhydroxyalkanoate

During the mid-1980's, several research groups were actively identifying and isolating the genes and gene products responsible for PHA synthesis. These efforts led to the development of transgenic systems for production of PHAs in both microorganism and plants, as well as enzymatic methods for PHA synthesis. Such routes could increase further the available PHA types. These advances have been reviewed in Williams & Peoples, *CHEMTECH*, 26:38-44 (1996) and Williams & Peoples, *Chem. Br.* 33:29-32 (1997).

Methods which can be used for producing PHA polymers suitable for subsequent modification to alter their rates of degradation are described, for example, in U.S. Patent No. 4,910,145 to Holmes, et al.; Byrom, "Miscellaneous Biomaterials" in Biomaterials (Byrom, Ed.), pp. 333-59 (MacMillan Publishers, London 1991); Hocking & Marchessault, "Biopolyesters" in Chemistry and Technology of Biodegradable Polymers (Griffin, Ed.), pp.48-96 (Chapman and Hall, London 1994); Holmes, "Biologically Produced (R)-3-hydroxyalkanoate Polymers and Copolymers," in Developments in Crystalline Polymers (Bassett Ed.), vol. 2, pp. 1-65 (Elsevier, London 1988); Lafferty *et al.*, "Microbial Production of Poly-b-hydroxybutyric acid" in Biotechnology (Rehm & Reed, Eds.) vol. 66, pp. 135-76 (Verlagsgesellschaft, Weinheim 1988); Müller & Seebach, *Angew. Chem. Int. Ed. Engl.* 32:477-502 (1993); Steinbüchel, "Polyhydroxyalkanoic Acids" in Biomaterials (Byrom, Ed.), pp. 123-213 (MacMillan Publishers, London 1991); Williams & Peoples, *CHEMTECH*,

26:38-44, (1996); Steinbüchel & Wiese, *Appl. Microbiol. Biotechnol.*, 37:691-697 (1992); U.S. Patent Nos. 5,245,023; 5,250,430; 5,480,794; 5,512,669; and 5,534,432; Agostini, *et al.*, *Polym. Sci.*, Part A-1, 9:2775-87 (1971); Gross, *et al.*, *Macromolecules*, 21:2657-68 (1988); Dubois, *et al.*, *Macromolecules*, 26:4407-12 (1993); Le Borgne & Spassky, *Polymer*, 30:2312-19 (1989); Tanahashi & Doi, *Macromolecules*, 24:5732-33 (1991); Hori, *et al.*, *Macromolecules*, 26:4388-90 (1993); Kemnitzer, *et al.*, *Macromolecules*, 26:1221-29 (1993); Hori, *et al.*, *Macromolecules*, 26:5533-34 (1993); Hocking, *et al.*, *Polym. Bull.*, 30:163-70 (1993); Xie, *et al.*, *Macromolecules*, 30:6997-98 (1997); U.S. Patent No. 5,563,239 to Hubbs; U.S. Patent Nos. 5,489,470 and 5,520,116 to Noda, *et al.* The PHAs derived from these methods may be in any form, including a latex or solid form.

Identification, cloning and expression of the genes involved in the biosynthesis of PHAs from several microorganisms within recombinant organisms allow for the production of PHAs within organisms that are not native PHA producers. A preferred example is *E.coli*, which is a well recognized host for production of biopharmaceuticals, and PHAs for medical applications. Such recombinant organisms provide a greater degree of control of the PHA production process because they are free of background enzyme activities for the biosynthesis of unwanted PHA precursors or degradation of the PHA. Additionally, the proper selection of a recombinant organism facilitates purification of, or allows for increased biocompatibility of, the produced PHA.

The minimal requirements for the synthesis of PHA in a recombinant organism are a source of hydroxyalkanoyl-CoA and an appropriate PHA synthase (Gemgross & Martin, *Proc. Natl. Acad. Sci.* 92:6279-83(1995)). Recombinant PHA producers thus require a biosynthetic pathway for a hydroxyalkanoyl-CoA monomer and a suitable PHA synthase. Production of a homopolymer requires that the organism produce only one suitable substrate for the PHA synthase, as production of multiple substrates results in the formation of a PHA copolymer.

(2) **Formation of 3-hydroxyacyl-CoA via CoA-dependent aldehyde dehydrogenase**

Propionic acid has been the standard co-feed used for the production of 3HV-containing PHAs (Luzier, 1992, Proc. Natl. Acad. Sci. USA 89:839-842).

5 The co-feeding strategy has the advantage that a single fermentation strain can be used to produce a PHA polymer type, usually PHBV where the 3HV concentration in the polymer can be directly controlled by modulating the level of the co-feed. Propionic acid is an anti-microbial agent, however, and therefore
10 Increasing the level of the propionic acid co-feed results in a major increase in the fermentation time. Alternative co-feed substrates that can be used to produce 3HV-containing PHAs include threonine, odd chain fatty acids such as valerate, heptanoate, etc., and odd chain alcohols.

To become part of PHA metabolism, propionic acid must be activated by coenzyme A. Therefore an active CoA transferase or CoA synthetase must be
15 present in the cell. In *E. coli*, this function is carried out by the *ato* system. The AtoDA complex is likely responsible for both uptake and CoA transfer to propionate (Jenkins and Nunn, 1987, J. Bacteriol. 169:42-52). Thus it is useful when feeding propionate to PHBV-producing *E. coli* to use a strain which constitutively expresses *atoC*, the positive regulator of the *ato* system (Jenkins
20 and Nunn, 1987, J. Bacteriol. 169:2096-2102). Propionyl-CoA is condensed with acetyl-CoA to give 3-hydroxyvaleryl-CoA, the activated monomer to be incorporated by the PHA synthase.

Conversion of other co-feeds such as 1-propanol or propylene glycol to propionic acid also requires a CoA synthetase or CoA transferase. Both of these
25 co-feeds are metabolized via propionaldehyde, which may then be converted to free propionic acid.

A CoA-dependent aldehyde dehydrogenase can serve to convert propionaldehyde directly to propionyl-CoA, thus alleviating the need for a separate CoA synthetase or CoA transferase and avoiding the presence of free
30 propionic acid in the cytosol. Propionyl-CoA is then condensed with acetyl-

CoA by beta-ketothiolase to form beta-ketoacyl-CoA which is then reduced to the D-beta-hydroxyacyl-CoA by the reductase enzyme to provide the 3HV monomeric unit required for the production of copolymers containing 3HV.

The strategy is also useful for the production of other PHA copolymers.

- 5 For example, a CoA-dependent aldehyde dehydrogenase can convert other aldehydes to their corresponding acyl-CoA, for example, butyraldehyde to butyryl-CoA. Following uptake into the cell, the butanol is converted to butyrate, activated to butyryl-CoA and condensed with acetyl-CoA by beta-ketothiolase to form beta-ketohexanoyl CoA which is then reduced to the D-
10 beta-hydroxyacyl-CoA by the reductase enzyme and finally polymerized. Figure 1 summarizes the pathways used to generate propionyl-CoA from propylene glycol and 1-propanol and butyryl-CoA from butanol.

- Coenzyme A-dependent aldehyde dehydrogenase is well known. For example, Jones and Turner reported in 1984 two studies on the detection and
15 activities of CoA-dependent aldehyde dehydrogenase (Jones and Turner, *J. Gen. Microbiol* 130(Pt 2):299-308 (1984); Jones and Turner, *J. Gen. Microbiol.* 130(Pt 4):849-60 (1984)). In one embodiment, the CoA-dependent aldehyde dehydrogenase is encoded by the *eutE* gene of *E. coli*. Many other useful CoA-dependent aldehyde dehydrogenases are encoded by genes of other species such
20 as described in Toth, et al., "The *ald* Gene, Encoding a Coenzyme A-Acylating Aldehyde Dehydrogenase, Distinguishes *Clostridium beijerinckii* and Two other Solvent-Producing Clostridia from *Clostridium acetobutylicum*" in *Applied and Environmental Microbiology* 65(11):4973-80 (1999).

- Homologs of this CoA-dependent aldehyde dehydrogenase encoded by
25 *E. coli* exist in other organisms. One can find candidate enzymes that may have the same type of activity by sequence homology which can be determined by enzyme assays. Examples of such genes are *Salmonella typhimurium eutE* (GenBank Accession No. U18560), *Listeria innocua eutE* (AL596167), *Clostridium beijerinckii* coenzyme A-acylating aldehyde dehydrogenase
30 (AF157306), *Salmonella typhimurium pduP* (AF026270), *Vibrio cholerae*

alcohol dehydrogenase/acetaldehyde dehydrogenase (AE004277), the aldehyde dehydrogenase segment of *E. coli adhE* (M33504), *Yersinia pestis* aldehyde-alcohol dehydrogenase (AJ414151), *Streptococcus pneumoniae* TIGR4 alcohol dehydrogenase, iron-containing (AE007491), *Clostridium kluyveri* CoA-dependent succinate semialdehyde dehydrogenase (L21902), and *Lactococcus lactis* alcohol-acetaldehyde dehydrogenase (AJ001008). Many other candidates can be found by using alignment techniques and databases such as GenBank at <http://www.ncbi.nlm.nih.gov/blast/>.

Propionaldehyde can be generated from a precursor substrate such as 1-propanol or propylene glycol and butyraldehyde can be produced from butanol. Examples of enzymes that can catalyze these conversions are diol oxidoreductase (Johnson and Lin, 1987, J. Bacteriol. 169:2050-2054; Daniel et al., 1995, J. Bacteriol. 177:2151-2156) and glycerol or diol dehydratase (Poznanskaya and Korsova, 1983, Biokhimiya 48:539-543; Tobimatsu et al., 1996, J. Biol. Chem. 271:22352-22357) from *Klebsiella pneumoniae*, *Citrobacter freundii*, or one of several other organisms. These enzymes are found in organisms capable of converting glycerol to 1,3-propanediol, although homologs may be found in other organisms by searching databases of sequenced genes and genomes. Glycerol or diol dehydratase can convert propylene glycol to propionaldehyde in a coenzyme B₁₂-dependent reaction; diol oxidoreductase can convert 1-propanol to propionaldehyde in an NAD⁺-dependent reaction.

Analogous of CoA-dependent aldehyde dehydrogenase useable in the method described herein can be identified by using alignment techniques and databases such as GenBank at <http://www.ncbi.nlm.nih.gov/blast/>. Generally, useable analogs have a certain degree of sequence homology, for example of 60%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% or above homology, to the CoA-dependent aldehyde dehydrogenase. Sequences of known CoA-dependent aldehyde dehydrogenases in various different species are available from, for example, databases such as GenBank at <http://www.ncbi.nlm.nih.gov/blast/>.

Organisms provided herein contain genes encoding one or more enzymes of Coenzyme-A-dependent aldehyde dehydrogenase, acyl-CoA transferase, acyl-CoA synthetase, β -ketothiolase, acetoacetyl-CoA reductase and PHA synthase. These organisms produce poly (3-hydroxyalkanoate) homopolymers or co-polymers having 3-hydroxyalkanoate monomers other than 3-hydroxybutyrate, the 3-hydroxyalkanoate units being derived from the enzyme-catalyzed conversion of a chemical such as alcohols to 3-hydroxyacyl-CoA monomers and wherein at least one step in the conversion pathway involves a Co-enzyme A-dependent aldehyde dehydrogenase activity.

- 10 The organism can be a wild-type organism having a CoA-dependent aldehyde dehydrogenase activity or modified by gene mutation to have the CoA-dependent aldehyde dehydrogenase activity, or a recombinant organism in which a gene is expressed to encode the CoA-dependent aldehyde dehydrogenase. The organism can be one of bacteria, plants, yeast, and fungi.
- 15 In one embodiment, the organism is bacteria such as *E. coli*. In another embodiment, the organism is a plant.

 In one embodiment, the method described herein can be used to produce PHBV copolymers incorporating various levels of 3HV units. For example, the method provided herein can be used to produced PHA copolymers having about 20 30 mol% of 3HV units.

III. PHA compositions and the use thereof for as medical devices

 The polymers described herein can form various polymer compositions, which are useful for, for example, films, latexes, coatings, adhesives, fibers, binders, resins and biodegradable medical devices.

- 25 Devices prepared from the PHA copolymers described herein can be used for a wide range of different medical applications. Examples of such applications include devices for controlled release of therapeutic, prophylactic or diagnostic agents, drug delivery, tissue engineering scaffolds, cell encapsulation; targeted delivery, biocompatible coatings, biocompatible implants, guided tissue

regeneration, wound dressings, orthopedic devices, prosthetics and bone cements (including adhesives and/or structural fillers), and diagnostics.

The PHA copolymers described herein can be used to encapsulate, be mixed with, or be ionically or covalently coupled to any of a variety of therapeutic, prophylactic or diagnostic agents. A wide variety of biologically active materials can be encapsulated or incorporated, either for delivery to a site by the polyhydroxyalkanoate, or to impart properties to the polymer, such as bioadhesion, cell attachment, enhancement of cell growth, inhibition of bacterial growth, and prevention of clot formation.

Examples of suitable therapeutic and prophylactic agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes. Compounds with a wide range of molecular weight can be encapsulated, for example, between 100 and 500,000 grams or more per mole. Specific examples include proteins such as receptor ligands, antibodies, enzymes, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator; antigens for immunization; hormones and growth factors; peptides such as adhesion peptides, polysaccharides such as heparin; oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy. The polymer can also be used to encapsulate cells and tissues. Representative diagnostic agents are agents detectable by x-ray, fluorescence, magnetic resonance imaging, radioactivity, ultrasound, computer tomography (CT) and positron emission tomography (PET). Ultrasound diagnostic agents are typically a gas such as air or perfluorocarbons.

The compound is typically incorporated into the PHAs in a percent loading of between 0.1% and 70% by weight, more preferably between 5% and 50% by weight. The PHAs may be in almost any physical form, such as a

powder, film, molded item, particles, spheres, latexes, and crystalline or amorphous materials. They can be combined with additional non-PHA materials, for example, other polymers. They are suitable for use in applications requiring slowly degrading, biocompatible, moldable materials, for example, medical devices. Examples of medical devices which can be prepared from the polymers include rods, bone screws, pins, surgical sutures, stents, tissue engineering devices, drug delivery devices, wound dressings, and patches such as hernial patches and pericardial patches.

Degradable implants fabricated with the PHA copolymers described herein may be used in a wide range of orthopedic and vascular applications, tissue engineering, guided tissue regeneration, and applications currently served by other thermoplastic elastomers (McMillin, *Rubber Chem. Technol.*, 67:417-46 (1994)). The implants may include other factors to stimulate repair and healing. Preferred devices are tubes suitable for passage of bodily fluids. These devices may be modified with cell attachment factors, growth factors, peptides, and antibodies and their fragments.

Preferred methods of fabricating medical devices include solvent casting, melt processing, extrusion, injection and compression molding, and spray drying. Particles are preferably prepared directly from a fermentation based process, or by a solvent evaporation technique, double emulsion technique, or by microfluidization, using methods available in the art. (Koosha, F. Ph.D. Dissertation, 1989, Univ. Nottingham, UK., *Diss. Abstr. Int. B* 51:1206 (1990); Bruhn, B.W. and Müller, B.W. *Proceed. Intern. Symp. Control. Rel. Bioact. Mater.* 18:668-69 (1991); Conti, B. *et al.*, *J. Microencapsulation*, 9:153-166 (1992); Ogawa, Y. *et al.*, *Chem. Pharm. Bull.*, 36:1095-103 (1988); Mathiowitz, E. and Langer, R. "Polyanhydride microspheres as drug delivery systems," M. Donbrow Ed., in "*Microcapsules Nanopart. Med. Pharm.*" CRC, Boca Raton, Florida, 1992, Ch. 5, pp. 99-123.)

The PHA copolymers described herein can be fabricated into devices for use in wound healing. For example, non-woven fibrous materials may be

prepared from the polymers by first producing polymer fibers, by pressing the polymers through a perforated outlet, using procedures known to those skilled in the art. The fibers can then be fabricated into a porous membrane (cloth) by spreading them on a solid support and subjecting them to compression molding.

- 5 The thickness of the device is preferably less than 500 μm . The wound healing device may also be prepared by perforating a film or membrane using a laser to achieve porosity, or using a leaching technique to prepare a porous material. The pore sizes should ideally be small enough to lock out cells and other tissue matter. The wound healing devices may be positioned *in vivo* to separate tissues
10 and stimulate tissue regeneration.

The PHA copolymers described herein may be used to encapsulate cells. Using procedures known to those skilled in the art, cells first may be pre-coated. Maysinger, *Reviews in the Neurosciences*, 6:15-33 (1995). Using a particle encapsulation procedure such as the double emulsion technique, the cells may
15 then be encapsulated by PHAs. Ogawa, *et al.*, *Chem. Pharm. Bull.*, 36:1095-103 (1988). Encapsulated cells may then be implanted *in vivo*.

The PHA polymers described herein may be fabricated into tissue engineering scaffolds using a wide range of polymer processing techniques. Preferred methods of fabricating PHA tissue engineering scaffolds include
20 solvent casting, melt processing, fiber processing/spinning/weaving, extrusion, injection and compression molding, lamination, and solvent leaching/solvent casting. Such methods are known to those skilled in the art.

One preferred method of fabricating a PHA copolymers described herein tissue engineering scaffold involves using an extruder, such as a Brabender
25 extruder. For example, this technique can be used to prepare extruded tubes suitable for implantation in a range of lengths and sizes.

Another preferred method involves preparing a nonwoven PHA scaffold from fibers. Fibers may be produced from the melt or solution, and processed into nonwovens using methods known to those skilled in the art. The properties
30 of the nonwoven may be tailored by varying, for example, the PHA material, the

fiber dimensions, fiber density, material thickness, fiber orientation, and method of fiber processing. The porous membranes may, if desired, be further processed. For example, these membranes may be formed into hollow tubes.

Another preferred method involves melt or solvent processing a suitable
5 PHA into an appropriate mold and perforating the material using a laser or other means to achieve the desired porosity. Also preferred are methods that include rolling a compression molded PHA sheet into a loop and heat sealing. The PHA sheet optionally may be rolled with another material, such as a second
10 biodegradable polymer. For example, the latter material could be a nonwoven of polyglycolic acid, polylactic acid, or a copolymer of glycolic and lactic acids. Such a procedure should provide a laminated tube suitable for use in the engineering of new vessels, ducts and tubes. The PHAs may also be used to coat other tissue engineering scaffolds. Such materials could be derived from other degradable polymers. Coating may be performed, for example, with a
15 solvent based solution, or by melt techniques, or using a PHA latex.

The tissue engineering devices described herein may be seeded with cells prior to implantation or after implantation. The cells may be harvested from a healthy section of the donor's tissue, expanded *in vitro* using cell culture techniques, and then seeded into a scaffold (or matrix) either prior to or after
20 implantation. Alternatively, the cells may be obtained from other donor's tissue or from existing cell lines.

The PHA copolymers described herein may be used to coat other devices and materials. Such coatings may improve their properties for medical application, for example, improving their biocompatibility, mechanical properties,
25 and tailoring their degradation and controlled release profiles. The PHA copolymers described herein may be coated onto other devices using the fabrication procedures described above. The thickness of the coating can be adjusted to the needs of the specific application by changing the coating weight or concentration applied, and/or by overcoating.

The PHA copolymers described herein may be fabricated into stents using a wide range of polymer processing techniques. Preferred methods of fabricating PHA stents include solvent casting, melt processing, fiber processing/spinning, extrusion, injection molding, and compression molding.

5 Such methods are known to those skilled in the art.

Prior to implantation, a bioresorbable polymeric article must be sterilized to prevent disease and infection of the recipient. Sterilization is performed prior to seeding a polymeric device with cells. Heat sterilization of PHA containing articles is often impractical since the heat treatment could deform the article,
10 especially if the PHA has a melting temperature below that required for the heat sterilization treatment. This problem can be overcome using cold ethylene oxide gas as a sterilizing agent. Exposure of a PHA containing article to vapors of ethylene oxide prior to implantation sterilizes the article making it suitable for implantation. During sterilization with cold ethylene oxide gas, the PHA
15 containing article maintains its shape. This type of treatment is ideally suited for sterilization of molded, or pre-formed articles where the shape of the article plays an important role in its proper functioning.

The devices described herein can be administered systemically or locally, or even used *in vitro*, particularly for cell culture. The preferred
20 methods of systemically administering devices such as microparticles are by injection, inhalation, oral administration and implantation. Other suitable methods for administering the devices include administering the devices topically, in a lotion, ointment, patch, or dressing.

The following examples further illustrate the methods and copolymers
25 disclosed herein.

Example 1. Isolation and identification of CoA-dependent aldehyde dehydrogenase

Because of its homology to the gene encoding the CoA-dependent aldehyde dehydrogenase component of the multifunctional alcohol

dehydrogenase protein (AdhE) of *E. coli*, the *eutE* gene was amplified from the *E. coli* genome using the following oligonucleotide primers:

5' — GGT GGT ACC TTA AGA GGA GGT TTT TAT GAA TCA ACA GGA
5 TAT TGA ACA — 3' (*eutE* 5' *Acc65I*)

5' — GGT GCG GCC GCT TAA ACA ATG CGA AAC GCA TCG — 3' (*eutE*
3' *NotI*)

10 The PCR product was digested with *Acc65I* and *NotI* and ligated to pSE380 (Invitrogen; La Jolla, CA) that had been cut with the same enzymes. The resulting plasmid, which contained the *eutE* gene under control of the IPTG-inducible *trc* promoter, was designated pMS35.

E. coli DH5a propagating either pMS35 or pTrcN (the same as pTrc99a,
15 Pharmacia; Uppsala, Sweden except with the *NotI* restriction site eliminated) was grown overnight in 2 mL Luria-Bertani (LB) broth (Difco; Detroit, Mich.) plus 100 µg/mL ampicillin at 37 °C with shaking at 250 rpm. These were used as inocula for 100-mL cultures of the same medium, which were grown at 37 °C with shaking in 250-mL Erlenmeyer flasks until the optical density at 600 nm
20 had reached 0.55 for the pTrcN-containing cells and 0.57 for the pMS35-containing cells. Then 1.3 mM IPTG was added, and the incubations were continued for 2 hours. The cells were removed from the medium by centrifugation for 10 min at 2000 x g, washed once in 50 mM potassium phosphate (pH 7.0), centrifuged again, and frozen at -20 °C. The cells were
25 prepared for sonication by resuspension in a small volume of ice-cold 50 mM AMPD (pH 8.5). Sonication was carried out with a microtip for 2 minutes (0.7 seconds on, 0.3 seconds off). The crude cell extracts were obtained by spinning the sonicated cells for 10 min in an Eppendorf 5415C microcentrifuge (Brinkmann Instruments, Inc.; Westbury, N.Y.) at maximum speed at 4 °C and
30 collecting the supernatant. The final assay mixture contained AMPD (pH 8.5, 50 mM), dithiothreitol (5 mM), NAD⁺ (2 mM), coenzyme A (0.5 mM), 1-5 µL/mL crude cell extract, and 15 mM propionaldehyde. In a quartz cuvette, all

components except for the aldehyde were combined and mixed well. After a steady absorbance reading at 340 nm was established, propionaldehyde was added and mixed by pipetting. The initial rate of change of absorbance was used to calculate the enzyme activity assuming an extinction coefficient of 6.22 mM⁻¹ cm⁻¹ for NADH. Alternatively, the assay was done with no coenzyme A. One unit of enzyme activity was defined as the amount of enzyme necessary to reduce 1 μmol of propionaldehyde per min. When CoA was included, the pTrcN extract showed no activity, but the pMS35 extract gave an activity of about 13 U/mg total protein when both 10.5 and 52.5 μg protein/mL were used. Without CoA, neither extract was active. Thus it was concluded that *eutE* encodes a CoA-dependent aldehyde dehydrogenase.

The same assay was done on a separate pair of extracts, generated in the same way as above, but with butyraldehyde as the substrate. The extracts were from *E. coli* DH5a once again, and this time pMS35 was compared to pMS31, which is analogous to pMS35 except that it contains the *E. coli aldA* gene. The pMS31 extract (at up to 170 μg protein/mL) showed no activity, whether or not coenzyme A was added to the assay mixture. The pMS35 extract gave an average activity of 5.9 U/mg total protein when 7.5 to 15.0 μg protein/mL were used. Without CoA, however, the pMS35 extract at the same concentrations gave an average of only about 0.1 U/mg total protein. Thus the EutE protein also acts on butyraldehyde in a CoA-dependent manner.

Example 2. Difference in toxicity between propionate and 1-propanol.

E. coli strain MBX1335 was grown in the presence of propionate or 1-propanol to compare the inhibition of growth rate effected by these compounds. One important reason for finding alternatives to propionate feeding is that propionate slows the rate of growth and metabolism in fermentations.

MBX1335 was grown overnight in LB medium supplemented with 25 μg/mL chloramphenicol. This culture was used to inoculate several 3-mL cultures of minimal medium supplemented with varying concentrations of propionate or 1-propanol. The base medium in these 3-mL cultures contained,

per liter: 5 g glucose; 1 mmol MgSO₄; 10 mg thiamine; 25.5 mmol Na₂HPO₄; 33.3 mmol K₂HPO₄; 27.2 mmol KH₂PO₄; 2.78 mg FeSO₄·7H₂O; 1.98 mg MnCl₂·4H₂O; 2.81 mg CoSO₄·7H₂O; 0.17 mg CuCl₂·2H₂O; 1.67 mg CaCl₂·2H₂O; 0.29 mg ZnSO₄·7H₂O; 0.1 g casein hydrolysate; and 25 µg chloramphenicol. This medium also contained either sodium propionate (pH 7), 1-propanol, or no added substrate. The propionate and 1-propanol concentrations used were 2, 5, and 10 g/L. The experiment for each of these cases was done in triplicate. Figure 2 shows the growth curves determined for each case. Clearly propionate inhibits the rate of growth substantially more than 1-propanol.

If the cultures are allowed to continue to grow, it should be noted that even though the cells grow more slowly in the presence of propionate, eventually they reach a higher optical density than in the presence of 1-propanol, presumably because they can use propionate as a carbon source for growth. The cultures with 10 g/L propionate, for example, reached an average OD-600 of 5.0, while the cultures with 10 g/L 1-propanol reached 3.8 and the cultures with no inhibitor reached 3.7. It is not desirable for the cells to grow on the co-feed because they can use the less-expensive primary feed for this purpose. Hence, 1-propanol may offer the additional advantage that it is converted more completely to PHBV and not used up by other cellular metabolism.

Example 3. PHBV production from glucose and 1-propanol in wild-type and alcohol dehydrogenase-deregulated strains.

The *Escherichia coli* strains DC675 and DC698 are described in Clark and Rod, J. Mol. Evol. 25:151-158 (1987). Strain DC698 is a regulatory mutant which produces alcohol dehydrogenase (the product of the *adhE* gene) constitutively. Strain DC675, from which DC698 was derived, only produces alcohol dehydrogenase under anaerobic conditions, as is generally true for wild-type *E. coli* strains. Each of these strains was transduced with a bacteriophage P1 lysate of *E. coli* strain MBX1335, which stably expresses PHB synthesis genes from the chromosome.

A bacteriophage P1 lysate of MBX1335 was made as follows:

MBX1335 was grown to an optical density (600 nm) of about 0.2 in 3 mL Luria broth (LB). Calcium chloride was added to 10 mM, and 30 μ L of a P1 lysate made previously was added. The mixture was incubated at 37°C for 4 h. After the incubation, 50 μ L of chloroform was added, and the mixture was agitated vigorously. The supernatant was collected by centrifuging for 3 min in a microcentrifuge at top speed and pipetting into a screw-cap glass tube. An addition of 30 μ L chloroform was made, and the resulting mixture was stored at 4°C.

Transductions were carried out on strains DC675 and DC698 as follows: each strain was grown to stationary phase in 2 mL of LB medium, and calcium chloride was added to 10 mM. In microcentrifuge tubes, 200 μ L of each culture was combined with 100 μ L of the P1 lysate described above or plain LB medium. These four tubes were incubated at 37°C for 15 min, then 100 μ L of 1 M sodium citrate and 500 μ L LB were added to each. After a further incubation at 37°C for 30 min, the cells were removed from the liquid by centrifuging for 10 sec in a microcentrifuge at top speed. Each pellet was resuspended in 100 μ L of 100 mM sodium citrate, and the contents of each tube were plated onto selective agar medium (LB supplemented with 25 μ g/mL chloramphenicol). The plates were incubated overnight at 37°C, and only the cultures treated with lysate yielded colonies. One colony was taken from each of these two plates. The DC675 transductant was denoted MBX1579, and the DC698 transductant was denoted MBX1580.

Strains MBX1579 and MBX1580 were grown overnight at 37°C with shaking in 2 mL of a medium containing, per liter: 5 g glucose; 1 mmol MgSO_4 ; 10 mg thiamine; 25.5 mmol Na_2HPO_4 ; 33.3 mmol K_2HPO_4 ; 27.2 mmol KH_2PO_4 ; 2.78 mg $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$; 1.98 mg $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$; 2.81 mg $\text{CoSO}_4 \cdot 7\text{H}_2\text{O}$; 0.17 mg $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$; 1.67 mg $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$; 0.29 mg $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$; and 25 μ g chloramphenicol. These cultures were then added to 50 mL of the same medium as above, and 15 mL of 2xYT medium (Difco; Detroit, Mich.) was added to

each for a total volume of 65 mL. These cultures were incubated at 37°C with shaking in 250-mL Erlenmeyer flasks for 16 hours. At the conclusion of this period, the cells were removed from the medium by centrifugation for 10 min at 2000 × g. They were then resuspended in 50 mL of a medium containing, per liter: 5 g glucose; 0 or 5 g 1-propanol; 7.75 g 2xYT powder; 1 mmol MgSO₄; 10 mg thiamine; 25.5 mmol Na₂HPO₄; 33.3 mmol K₂HPO₄; 27.2 mmol KH₂PO₄; 2.78 mg FeSO₄·7H₂O; 1.98 mg MnCl₂·4H₂O; 2.81 mg CoSO₄·7H₂O; 0.17 mg CuCl₂·2H₂O; 1.67 mg CaCl₂·2H₂O; 0.29 mg ZnSO₄·7H₂O; and 25 µg chloramphenicol. At the conclusion of this period, the cells were removed from the medium by centrifugation as above, washed with water, centrifuged again, and lyophilized. About 15 mg of lyophilized cell mass from each flask was subjected to simultaneous extraction and butanolysis at 110°C for 3 hours in 2 mL of a mixture containing (by volume) 90% 1-butanol and 10% concentrated hydrochloric acid, with 2 mg/mL benzoic acid added as an internal standard. The water-soluble components of the resulting mixture were removed by extraction with 3 mL water. The organic phase (1 µL at a split ratio of 1:50 at an overall flow rate of 2 mL/min) was analyzed on an SPB-1 fused silica capillary GC column (30 m; 0.32 mm ID; 0.25 µm film; Supelco; Bellefonte, Pa.) with the following temperature profile: 80°C, 2 min; 10 C° per min to 250°C; 250°C, 2 min. The standard used was PHBV (Aldrich Chemical Co.; Milwaukee, Wis.). The polymer content and composition for each culture is given in Table 1.

Table 1. PHBV production in MBX1579 and MBX1580 from glucose and 1-propanol.

Strain	1-Propanol (g/L)	PHA, % of dry cell weight	3HV, % of polymer weight
MBX1579	0	24.1	0.0
MBX1580	0	42.4	0.0
MBX1579	5	22.6	3.9
MBX1580	5	32.7	24.4

When 1-propanol is provided, MBX1579 is capable of incorporating some 3HV units into the polymer, but MBX1580, with constitutive alcohol dehydrogenase, incorporates about six times as much, in terms of the 3HV composition by weight percentage of the polymer. MBX1579 and MBX1580 largely have the same genetic background, and thus it appeared likely that the product of the *adhE* gene was at least partially responsible for this increase.

Example 4. PHBV from glucose and 1-propanol with plasmid-based strain.

Plasmid pMS72 contains both the *K. pneumoniae dhaT* gene and the *E. coli eutE* gene under the control of an IPTG-inducible promoter. pMS72 was constructed by inserting the *eutE* gene into pTC42 (Skraly et al., 1998, Appl. Environ. Microbiol. 64:98-105). The *eutE* gene was removed from pMS35 by digestion with *Bgl*II and *Spe*I. This fragment was ligated to pTC42 that had been digested with *Bgl*II and *Nhe*I (which shares a compatible sticky end with *Nhe*I).

E. coli strain MBX1335 was transformed with pMS72 to assess whether this construct was capable of converting glucose and 1-propanol to PHBV. MBX1335 transformed with pTrcN, the vector from which pMS72 was derived, was used as a control. Each strain was grown overnight in minimal glucose medium supplemented with 100 µg/mL ampicillin at 37 °C in a culture tube in a volume of 3 mL with shaking at 200 rpm. The minimal medium contained, per liter: 25.5 mmol Na₂HPO₄; 33.3 mmol K₂HPO₄; 27.2 mmol KH₂PO₄; 2.78 mg FeSO₄·7H₂O; 1.98 mg MnCl₂·4H₂O; 2.81 mg CoSO₄·7H₂O; 0.17 mg CuCl₂·2H₂O; 1.67 mg CaCl₂·2H₂O; 0.29 mg ZnSO₄·7H₂O; 1 mmol MgSO₄; 10 mg thiamine; 100 mg ampicillin; and 5 g glucose. This culture (0.1 mL) was used to inoculate a 200-mL square glass bottle containing 50 mL of the same medium. Added to each culture was 15 mL 2x YT medium (Difco; Detroit, Mich.). These 65-mL cultures were incubated with shaking at 37 °C for 6 hours with shaking at 200 rpm. At the conclusion of this period, the cells were removed from the medium by centrifugation for 10 min at 2000 × g. They were

then resuspended in 50 mL of the minimal glucose medium above, supplemented with 5 g/L 1-propanol; 0.5x YT; 100 µg/mL ampicillin; and 0, 0.01, or 0.05 mM IPTG. After an incubation of 90 hours at 30 °C, the cells were centrifuged as above, washed once with water, centrifuged again, and lyophilized. The dried cell mass was subjected to butanolysis as described above, and the GC results are as listed in Table 2.

Table 2. PHBV production in MBX1335 from glucose and 1-propanol.

Plasmid	IPTG (mM)	PHA, % of dry cell weight	3HV, % of polymer weight
pTrcN	0	19.1	0.0
pTrcN	0.01	16.1	3.3
pTrcN	0.05	18.8	3.5
pMS72	0	14.0	0.0
pMS72	0.01	6.6	9.7
pMS72	0.05	6.5	26.3

Thus pMS72 enables MBX1335 to synthesize PHBV from glucose and 1-propanol much more efficiently than without the plasmid.

Example 5. PHBV from glucose and 1,2-propanediol with plasmid-based strain.

Escherichia coli strain MBX1335 containing the plasmid pFS83 (which contains the *Klebsiella pneumoniae* glycerol dehydratase, or *dhaB*, gene and the *E. coli eutE* aldehyde dehydrogenase gene) was grown for 6 hours at 37 °C in LB medium in a culture tube in a volume of 3 mL with shaking at 200 rpm. This culture (0.25 mL) was used to inoculate a 250-mL Erlenmeyer flask containing 50 mL of a medium containing, per liter: 25.5 mmol Na₂HPO₄; 33.3 mmol K₂HPO₄; 27.2 mmol KH₂PO₄; 2.78 mg FeSO₄·7H₂O; 1.98 mg MnCl₂·4H₂O; 2.81 mg CoSO₄·7H₂O; 0.17 mg CuCl₂·2H₂O; 1.67 mg CaCl₂·2H₂O; 0.29 mg ZnSO₄·7H₂O; 10 g glucose; 1 mmol MgSO₄; 10 mg thiamine; 0.1 g casein hydrolysate; 0.01 mmol isopropyl-β-D-thiogalactopyranoside (IPTG); 100 mg ampicillin; 0 or 20 nmol coenzyme B-12; and 0, 5, or 10 g 1,2-propanediol. These 50-mL cultures were incubated with

shaking at 30 °C for 24 hours with shaking at 200 rpm. At the conclusion of this period, the cells were removed from the medium by centrifugation for 10 min at 2000 × g. They were washed once with water, centrifuged again, and lyophilized. The dried cell mass was subjected to butanolysis as described above, and the GC results are as listed in Table 3.

Table 3. PHBV production in MBX1335/pFS83 from glucose and 1,2-propanediol.

Coenzyme B-12 (nM)	1,2-Propanediol (g/L)	PHA, % of dry cell weight	3HV, % of polymer weight
0	0	58.8	0.0
0	5	54.8	0.0
0	10	54.9	0.0
20	0	57.6	0.0
20	5	49.3	10.9
20	10	38.3	16.9

PHBV is formed only in the presence of both coenzyme B-12 and 1,2-propanediol, strongly suggesting that the action of the coenzyme B-12-dependent glycerol dehydratase is responsible for the conversion of 1,2-propanediol to propionaldehyde, which is ultimately incorporated into the polymer as 3HV.

The plasmid pFS83 was constructed by taking the *eutE* gene from pMS35 as an *XbaI-HindIII* fragment and ligating this fragment to pFS44B cut with *SpeI* and *HindIII*. Plasmid pFS44B was constructed by ligating the *Sall-NheI* fragment of pTC53 (Skraly et al., 1998, Appl. Environ. Microbiol. 64:98-105) containing the *dhaB* gene to the vector pSE380 (Invitrogen; Carlsbad, CA) that had been digested with the same restriction enzymes.

Example 6. PHBV from glucose and 1-propanol with integrated strain.

Several *Escherichia coli* strains were constructed by integration of the *K. pneumoniae dhaT* and *E. coli eutE* genes, along with the *tetA* gene from *Tn10*, into the chromosome of MBX1335. The integration was accomplished with the plasmid pUT-*eutE-dhaT-tetA*, a derivative of pUTHg (Herrero et al., 1990, J. Bacteriol. 172: 6557-6567). To construct pUT-*eutE-dhaT-tetA*, first the *tetA*

gene was amplified by PCR from *Tn10* using the following oligonucleotide primers:

5' — GGT CCT AGG TTA AGA GGA GGT TTT TAT GAA TAG TTC GAC
5 AAA GAT CGC — 3' (*tetA* 5' *AvrII*)

5' — GGT ACT AGT CTA AGC ACT TGT CTC CTG TTT AC — 3' (*tetA* 3' *SpeI*)

- 10 The *tetA* PCR product was digested with *AvrII* and *SpeI* and ligated to pUTHg that had been digested with *AvrII* (*AvrII* and *SpeI* give compatible sticky ends). This resulted in plasmid pUT-*tetA*. The *eutE* and *dhaT* genes were taken from pMS72 by digestion with *SalI* and *SpeI* and ligated to pUC18Sfi (Herrero et al., *ibid.*) which had been digested with *SalI* and *XbaI*. This resulted in plasmid
- 15 pMS77. Then the *eutE-dhaT* fragment was taken from pMS77 by digestion with *AvrII*, and it was ligated to pUT-*tetA* that had been digested with *AvrII*, to form pUT-*eutE-dhaT-tetA*. After conjugation, the donor-recipient mixture was immediately grown in LB supplemented with 15 $\mu\text{g/mL}$ tetracycline and 25 $\mu\text{g/mL}$ chloramphenicol for about 40 generations by serial culturing at 37 °C.
- 20 This enriched population was plated onto LB agar supplemented with the same antibiotics.

Several colonies were isolated from platings such as this and were tested for their ability to synthesize PHBV from glucose and 1-propanol. MBX1335 (from which it was derived) was used as a control. Each strain was grown for 8

25 hours in LB medium supplemented with 25 $\mu\text{g/mL}$ chloramphenicol, 50 $\mu\text{g/mL}$ kanamycin, and 10 $\mu\text{g/mL}$ tetracycline at 37 °C in a culture tube in a volume of 3 mL with shaking at 200 rpm. This culture (1 mL) was used to inoculate a 500-mL Erlenmeyer flask containing 100 mL of a medium containing, per liter: 25.5 mmol Na_2HPO_4 ; 33.3 mmol K_2HPO_4 ; 27.2 mmol KH_2PO_4 ; 2.78 mg

30 $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$; 1.98 mg $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$; 2.81 mg $\text{CoSO}_4 \cdot 7\text{H}_2\text{O}$; 0.17 mg

CuCl₂·2H₂O; 1.67 mg CaCl₂·2H₂O; 0.29 mg ZnSO₄·7H₂O; 10 g glucose; 5
 mmol MgSO₄; 10 mg thiamine; 0.1 g casein hydrolysate; 25 mg
 chloramphenicol; 50 mg kanamycin; 10 mg tetracycline; and 7 g/L 1-propanol.
 These 100-mL cultures were incubated with shaking at 30 °C for 46 hours with
 5 shaking at 200 rpm. At the conclusion of this period, the cells were removed
 from the medium by centrifugation for 10 min at 2000 × g. They were washed
 once with water, centrifuged again, and lyophilized. The dried cell mass was
 subjected to butanolysis as described above, and the GC results are as listed in
 Table 4. In a separate experiment, the activities of the *eutE* and *dhaT* gene
 10 products were measured. The cells were grown as above, except with 4 g/L 1-
 propanol instead of 7 g/L 1-propanol, and the incubation at 30 °C was for 24 h
 instead of 46 h. Strain LS5218 was cultured to establish a background in 100
 mL LB for 8 hours at 37 °C. After the incubations, 50 mL of each culture was
 centrifuged as above, then washed once in 25 mL of a buffer containing 50 mM
 15 HEPES (pH 7.4), 2 mM dithiothreitol, and 0.1 mM MnCl₂, centrifuged again,
 and resuspended in 2 mL of the same buffer. The suspensions were sonicated
 with a microtip for 2 min (0.4 sec on, 0.4 sec off), and enzyme assays conducted
 as in Johnson and Lin, 1987, J. Bacteriol. 169:2050-4 for DhaT and as in Yan
 and Chen, 1990, *Appl. Environ. Microbiol.* 56: 2591-9 for EutE. Results are
 20 given in Table 4.

Table 4. PHBV production in integrants from glucose and 1-propanol.

Strain	Final OD- 600	Total PHA, % of dry cell wt.	3HV, % of polymer weight	EutE activity, U/mg	DhaT activity, U/mg
LS5218	—	—	—	0.03	0.00
MBX1635	11.8	57	4.6	0.21	0.09
MBX1865	11.1	68	12.6	0.33	0.41
MBX1866	11.3	68	5.9	0.27	0.12
MBX1914	10.8	64	9.7	0.30	0.39
MBX1915	10.5	63	10.6	0.24	0.41
MBX1916	10.7	73	11.4	0.39	0.30
MBX1917	9.3	64	7.6	0.31	0.26

Different integrated strains had differing abilities to incorporate 3HV into the polymer when fed 1-propanol, and these abilities roughly corresponded to activities of EutE and DhaT, the two enzymes responsible for conversion of 1-propanol to propionyl-CoA.

Example 7. PHBV from glucose and 1,2-propanediol with integrated strain.

Escherichia coli strain MBX1648 was constructed by integration of the *K. pneumoniae dhaB* and *E. coli eutE* genes, along with the *tetA* gene from *Tn10*, into the chromosome of MBX1335. The integration was accomplished with the plasmid pUT-dhaB-eutE-tetA, a derivative of pUTHg (Herrero et al., 1990, J. Bacteriol. 172: 6557-6567). To construct pUT-dhaB-eutE-tetA, first the *tetA* gene was amplified by PCR from *Tn10* as in the previous example. The *tetA* PCR product was digested with *AvrII* and *SpeI* and ligated to pUTHg that had been digested with *AvrII* (*AvrII* and *SpeI* give compatible sticky ends). This resulted in plasmid pUT-*tetA*. The *dhaB* and *eutE* genes were taken from pMS82 (pFS83 which was digested with *AvrII*, filled in by T4 DNA polymerase, and self-ligated, to remove the *AvrII* site) by digestion with *SalI* and *SpeI* and ligated to pUC18Sfi (Herrero et al., *ibid.*) which had been digested with *SalI* and *XbaI* (which shares a compatible sticky end with *SpeI*). This resulted in plasmid pMS83. Then the *eutE-dhaB* fragment was taken from pMS83 by digestion with *AvrII*, and it was ligated to pUT-*tetA* that had been digested with *AvrII*, to form pUT-*dhaB-eutE-tetA*. After conjugation, the donor-recipient mixture was immediately grown in LB supplemented with 15 $\mu\text{g/mL}$ tetracycline and 25 $\mu\text{g/mL}$ chloramphenicol for about 40 generations by serial culturing at 37 °C. This enriched population was plated onto LB agar supplemented with the same antibiotics. MBX1648 was one colony isolated from this plating.

MBX1648 was tested for its ability to synthesize PHBV from glucose and 1,2-propanediol. MBX1335 (from which it was derived) was used as a

control. Each strain was grown for 8 hours in LB medium supplemented with 25 $\mu\text{g/mL}$ chloramphenicol at 37 °C in a culture tube in a volume of 3 mL with shaking at 200 rpm. This culture (0.1 mL) was used to inoculate a 250-mL Erlenmeyer flask containing 50 mL of a medium containing, per liter: 25.5 mmol Na_2HPO_4 ; 33.3 mmol K_2HPO_4 ; 27.2 mmol KH_2PO_4 ; 2.78 mg $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$; 1.98 mg $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$; 2.81 mg $\text{CoSO}_4 \cdot 7\text{H}_2\text{O}$; 0.17 mg $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$; 1.67 mg $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$; 0.29 mg $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$; 10 g glucose; 1 mmol MgSO_4 ; 10 mg thiamine; 0.1 g casein hydrolysate; 25 mg chloramphenicol; and varying amounts of coenzyme B-12 and 1,2-propanediol, as indicated in Table 5. These 50-mL cultures were incubated with shaking at 30 °C for 46 hours with shaking at 200 rpm. At the conclusion of this period, the cells were removed from the medium by centrifugation for 10 min at $2000 \times g$. They were washed once with water, centrifuged again, and lyophilized. The dried cell mass was subjected to butanolysis as described above, and the GC results are as listed in Table 5.

Table 5. PHBV production in MBX1335/pFS83 from glucose and 1,2-propanediol.

Strain	Coenzyme B-12 (nM)	1,2-Propanediol (g/L)	PHA, % of dry cell weight	3HV, % of polymer weight
MBX1335	20	10	38.3	0.0
MBX1648	0	10	25.0	0.0
MBX1648	5	10	28.2	8.0
MBX1648*	10	10	2.0	39.0
MBX1648*	20	10	9.9	44.5
MBX1648	10	0	27.8	0.0
MBX1648	10	5	14.8	29.9
MBX1648*	10	20	27.2	23.8

* These cultures were fed 25.5 mM Na_2HPO_4 , 33.3 mM K_2HPO_4 , and 27.2 mM KH_2PO_4 at 16 h to alleviate acidity.

Thus MBX1648 can synthesize copolymers with significant 3HV content while maintaining overall polymer content under various conditions.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the methods and compositions described herein. Such equivalents are intended to be encompassed by the following claims.